Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 52.67% | Mizuho | $31 → $1 | Downgrades | Buy → Neutral |
| 09/26/2023 | 4174.81% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/21/2023 | 113.74% | Citigroup | $2 → $1.4 | Maintains | Sell |
| 08/09/2023 | 3716.79% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 06/14/2023 | 4174.81% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 05/09/2023 | 2953.44% | Canaccord Genuity | $50 → $20 | Maintains | Buy |
| 02/09/2023 | 3716.79% | EF Hutton | → $25 | Reiterates | → Buy |
| 02/09/2023 | 4022.14% | HC Wainwright & Co. | $29 → $27 | Maintains | Buy |
| 02/07/2023 | 4632.82% | Mizuho | → $31 | Reiterates | → Buy |
| 01/05/2023 | 3716.79% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 08/16/2022 | 4632.82% | Mizuho | $39 → $31 | Maintains | Buy |
| 08/09/2022 | 358.02% | Goldman Sachs | $4 → $3 | Maintains | Sell |
| 07/20/2022 | 358.02% | Citigroup | → $3 | Downgrades | Neutral → Sell |
| 07/13/2022 | 1426.72% | JP Morgan | → $10 | Downgrades | Overweight → Neutral |
| 07/13/2022 | 663.36% | Stifel | $16 → $5 | Downgrades | Buy → Hold |
| 05/24/2022 | 510.69% | Goldman Sachs | $5 → $4 | Maintains | Sell |
| 05/23/2022 | 4327.48% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 05/10/2022 | 1121.37% | Citigroup | $23 → $8 | Downgrades | Buy → Neutral |
| 03/28/2022 | 3258.78% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 01/03/2022 | 4022.14% | JP Morgan | $26 → $27 | Maintains | Overweight |
| 05/13/2021 | 4327.48% | JP Morgan | $23 → $29 | Upgrades | Neutral → Overweight |
| 05/05/2021 | 4632.82% | HC Wainwright & Co. | $32 → $31 | Maintains | Buy |
| 12/08/2020 | 4632.82% | HC Wainwright & Co. | $28 → $31 | Maintains | Buy |
| 11/10/2020 | 4174.81% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 09/15/2020 | 11808.4% | Canaccord Genuity | $70 → $78 | Maintains | Buy |
| 08/06/2020 | 4174.81% | Stifel | $30 → $28 | Maintains | Buy |
| 08/06/2020 | 3869.47% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 06/30/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/15/2020 | 3716.79% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 05/12/2020 | 3411.45% | JP Morgan | $22 → $23 | Maintains | Neutral |
| 04/23/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/08/2019 | 3258.78% | JP Morgan | $43 → $22 | Downgrades | Overweight → Neutral |
| 09/27/2019 | 1274.05% | Goldman Sachs | $14 → $9 | Downgrades | Neutral → Sell |
| 09/16/2019 | 2190.08% | Jefferies | $32 → $15 | Downgrades | Buy → Hold |
| 06/04/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 05/30/2019 | 4480.15% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 05/23/2019 | 6159.54% | Stifel | → $41 | Initiates Coverage On | → Buy |
| 01/23/2019 | 9365.65% | Mizuho | → $62 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 52.67% | 瑞穗市 | 31 美元 → 1 美元 | 降級 | 買入 → 中性 |
| 09/26/2023 | 4174.81% | HC Wainwright & Co. | → 28 美元 | 重申 | 購買 → 購買 |
| 08/21/2023 | 113.74% | 花旗集團 | 2 美元 → 1.4 美元 | 維護 | 賣出 |
| 08/09/2023 | 3716.79% | EF Hutton | → 25 美元 | 重申 | 購買 → 購買 |
| 06/14/2023 | 4174.81% | HC Wainwright & Co. | 27 美元 → 28 美元 | 維護 | 買 |
| 05/09/2023 | 2953.44% | Canaccord Genu | 50 美元 → 20 美元 | 維護 | 買 |
| 02/09/2023 | 3716.79% | EF Hutton | → 25 美元 | 重申 | → 購買 |
| 02/09/2023 | 4022.14% | HC Wainwright & Co. | 29 美元 → 27 美元 | 維護 | 買 |
| 02/07/2023 | 4632.82% | 瑞穗市 | → 31 美元 | 重申 | → 購買 |
| 01/05/2023 | 3716.79% | EF Hutton | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/16/2022 | 4632.82% | 瑞穗市 | 39 美元 → 31 美元 | 維護 | 買 |
| 08/09/2022 | 358.02% | 高盛 | 4 美元 → 3 美元 | 維護 | 賣出 |
| 07/20/2022 | 358.02% | 花旗集團 | → 3 美元 | 降級 | 中性 → 賣出 |
| 07/13/2022 | 1426.72% | 摩根大通 | → 10 美元 | 降級 | 超重 → 中性 |
| 07/13/2022 | 663.36% | Stifel | 16 美元 → 5 美元 | 降級 | 買入 → 持有 |
| 2022 年 5 月 24 日 | 510.69% | 高盛 | 5 美元 → 4 美元 | 維護 | 賣出 |
| 05/23/2022 | 4327.48% | HC Wainwright & Co. | 31 美元 → 29 美元 | 維護 | 買 |
| 05/10/2022 | 1121.37% | 花旗集團 | 23 美元 → 8 美元 | 降級 | 買入 → 中性 |
| 03/28/2022 | 3258.78% | 摩根大通 | 27 美元 → 22 美元 | 維護 | 超重 |
| 01/03/2022 | 4022.14% | 摩根大通 | 26 美元 → 27 美元 | 維護 | 超重 |
| 2021 年 5 月 13 日 | 4327.48% | 摩根大通 | 23 美元 → 29 美元 | 升級 | 中性 → 超重 |
| 2021 年 5 月 5 日 | 4632.82% | HC Wainwright & Co. | 32 美元 → 31 美元 | 維護 | 買 |
| 12/08/2020 | 4632.82% | HC Wainwright & Co. | 28 美元 → 31 美元 | 維護 | 買 |
| 11/10/2020 | 4174.81% | HC Wainwright & Co. | 26 美元 → 28 美元 | 維護 | 買 |
| 2020 年 9 月 15 日 | 11808.4% | Canaccord Genu | 70 美元 → 78 美元 | 維護 | 買 |
| 08/06/2020 | 4174.81% | Stifel | 30 美元 → 28 美元 | 維護 | 買 |
| 08/06/2020 | 3869.47% | HC Wainwright & Co. | 25 美元 → 26 美元 | 維護 | 買 |
| 06/30/2020 | — | Evercore ISI 集團 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 06/15/2020 | 3716.79% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/12/2020 | 3411.45% | 摩根大通 | 22 美元 → 23 美元 | 維護 | 中立 |
| 04/23/2020 | — | 花旗集團 | 升級 | 中性 → 買入 | |
| 11/08/2019 | 3258.78% | 摩根大通 | 43 美元 → 22 美元 | 降級 | 超重 → 中性 |
| 09/27/2019 | 1274.05% | 高盛 | 14 美元 → 9 美元 | 降級 | 中性 → 賣出 |
| 09/16/2019 | 2190.08% | 傑富瑞集團 | 32 美元 → 15 美元 | 降級 | 買入 → 持有 |
| 06/04/2019 | — | 花旗集團 | 升級 | 賣出 → 中立 | |
| 2019 年 5 月 30 日 | 4480.15% | 羅斯資本 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/23/2019 | 6159.54% | Stifel | → 41 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 1 月 23 日 | 9365.65% | 瑞穗市 | → 62 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的目標價格是多少？
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Mizuho on November 9, 2023. The analyst firm set a price target for $1.00 expecting ATRA to rise to within 12 months (a possible 52.67% upside). 10 analyst firms have reported ratings in the last year.
瑞穗於2023年11月9日公佈了Atara Biotherapeutics（納斯達克股票代碼：ATRA）的最新目標股價。該分析公司將目標股價定爲1.00美元，預計ATRA將在12個月內升至12個月內（可能上漲52.67％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的最新分析師評級是多少？
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Mizuho, and Atara Biotherapeutics downgraded their neutral rating.
瑞穗提供了Atara Biotherapeutics（納斯達克股票代碼：ATRA）的最新分析師評級，Atara Biotherapeutics下調了中性評級。
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Atara Biotherapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Atara Biotherapeutics的最新評級是在2023年11月9日發佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
分析師對Atara Biotherapeutics（ATRA）的評級是否正確？
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a downgraded with a price target of $31.00 to $1.00. The current price Atara Biotherapeutics (ATRA) is trading at is $0.66, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Atara Biotherapeutics（ATRA）評級已下調，目標股價爲31.00美元至1.00美元。阿塔拉生物療法（ATRA）目前的交易價格爲0.66美元，超出了分析師的預期區間。